Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Rhabdomyosarcoma, Alveolar

ClinicalTrials.gov lists 18 trials for Rhabdomyosarcoma, Alveolar or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 4.

MeSH D018232 Neoplasms Neoplasm C04 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 2 Phase 1/2 Phase 1/2 3 Phase 2 Phase 2 2 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 3 Phase 4 Phase 4 1 Not applicable Not applicable 5 Observational Observational 1 Phase 1 Phase 1 2 Phase 1/2 Phase 1/2 3 Phase 2 Phase 2 2 Phase 2/3 Phase 2/3 1 Phase 3 Phase 3 3 Phase 4 Phase 4 1 Not applicable Not applicable 5 Observational Observational 1

Trials per phase

18 of the 18 trials are tagged with Rhabdomyosarcoma, Alveolar itself; the rest are tagged with a narrower condition beneath it.

Get the Rhabdomyosarcoma, Alveolar report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Rhabdomyosarcoma, Alveolar trials start? (12)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 4

2006: 1 trials (Phase 1 1) 2007: 1 trials (Phase 1/2 1) 2009: 1 trials (Phase 4 1) 2011: 1 trials (Not applicable 1) 2012: 1 trials (Phase 2 1) 2013: 1 trials (Phase 2 1) 2016: 2 trials (Phase 3 1, Phase 1 1) 2017: 2 trials (Observational 1, Phase 1/2 1) 2021: 4 trials (Not applicable 1, Phase 3 2, Phase 1/2 1) 2022: 2 trials (Not applicable 2) 2023: 1 trials (Not applicable 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 1
2023 1
2022 2
2021 4
2017 2
2016 2
2013 1
2012 1
2011 1
2009 1

Showing 10 of 12 earlier years.

Start your 14-day trial Email me all 12 earlier years as a PDF

No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: none of the 18 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Rhabdomyosarcoma, Alveolar trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 2
Phase 1/2 3
Phase 2 2
Phase 2/3 1
Phase 3 3
Phase 4 1
Not applicable 5
Observational 1

How many Rhabdomyosarcoma, Alveolar trials are recruiting? (6)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 1
Recruiting 1
Active, not recruiting 4
Completed 7
Terminated 2

Showing 5 of 6 statuses.

Start your 14-day trial Email me all 6 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Rhabdomyosarcoma, Alveolar trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 4
C. R. Bard 2
Children's Oncology Group 2
European Organisation for Research and Treatment of Cancer - EORTC 1
Neotropix 1

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Rhabdomyosarcoma, Alveolar? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Dactinomycin 2
Cytoxan 2

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Vinorelbin 2
Radiation Therapy 2
Vincristina 2
Left Arm treated with vehicle serum and Intense Pulsed Light Therapy 1
Taclonex Ointment 1

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Rhabdomyosarcoma, Alveolar trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Restenosis 189 1
Other 86 1
Cardiovascular, Other 79 1
Stenosis 65 1
Carcinoma 46 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Rhabdomyosarcoma, Alveolar? (8)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Yes
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology 2019 Yes
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'. European journal of cancer (Oxford, England : 1990) 2018 Yes
Synergistic Antitumour Properties of <i>viscumTT</i> in Alveolar Rhabdomyosarcoma. Journal of immunology research 2017 Yes
Oral low-dose chemotherapy: successful treatment of an alveolar rhabdomyosarcoma during pregnancy. Pediatric blood & cancer 2012 Yes

Showing 5 of 8 publications.

Start your 14-day trial Email me all 8 publications as a PDF

Prevalence (69)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Alveolar rhabdomyosarcoma Annual incidence <1 / 1 000 000 United Kingdom GB Exact
Alveolar rhabdomyosarcoma Annual incidence <1 / 1 000 000 United Kingdom GB Unspecified
Alveolar rhabdomyosarcoma Annual incidence <1 / 1 000 000 United Kingdom GB Exact
Alveolar rhabdomyosarcoma Annual incidence <1 / 1 000 000 Finland Not stated Exact
Alveolar rhabdomyosarcoma Annual incidence <1 / 1 000 000 Latvia Not stated Unspecified

Showing 5 of 69 prevalence observations.

Start your 14-day trial Email me the first 50 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Alveolar rhabdomyosarcoma 99756 Exact Orphanet Rare Disease Ontology (ORDO)
Alveolar rhabdomyosarcoma 99756 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages